Can yeast protein keep muscles strong while GLP-1 drugs melt fat?
NCT ID NCT07817823
First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time
Summary
Researchers are testing whether a daily yeast protein supplement can protect lean body mass and muscle function in adults with overweight or obesity who are losing weight with GLP-1 receptor agonist drugs. The trial enrolls 200 adults aged 25 to 50 who are starting or have recently started GLP-1 treatment. Participants take yeast protein, whey protein, or a blend for 12 weeks. The team measures muscle mass with DXA scans, tests muscle function, and tracks metabolic and gut health markers to see which protein source works best.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- yeast protein supplement
- What this could lead to
- If yeast protein helps, it could offer a cheaper, more sustainable way to protect muscle during weight loss with GLP-1 drugs.
- What could go wrong
- This is a 12-week study of 200 people, so it cannot show long-term effects on muscle or health. Protein supplements may not overcome the muscle loss caused by rapid weight loss, and results might not apply to other groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 25-50 years with overweight or obesity, defined as BMI ≥24.0 kg/m², who meet the clinical indication for GLP-1RA-related weight-loss treatment. Planning to initiate GLP-1RA treatment, or having initiated GLP-1RA treatment within the previous 4 weeks, and intending to continue treatment for at least 12 weeks. Able and willing to provide written informed consent and comply with the 12-week intervention, follow-up visits, dietary assessments, body composition measurements, muscle function tests, and biological sample collection. Exclusion Criteria: * Known allergy or intolerance to yeast protein, whey protein, milk-derived ingredients, or other components of the study products. Unable to undergo dual-energy X-ray absorptiometry (DXA) or having a contraindication to DXA examination. Sarcopenia at baseline, defined by appendicular skeletal muscle mass index (ASMI) \<7.0 kg/m² in men or \<5.4 kg/m² in women. Severe cardiovascular or cerebrovascular disease, hepatic or renal insufficiency, malignancy, or other diseases that may substantially affect skeletal muscle metabolism. Regular use of protein powder or additional protein supplementation equivalent to ≥0.3 g/kg body weight per day. Initiation or dose adjustment of statins within the previous 3 months, or a history of statin-associated myopathy. Current participation in another weight-loss program or clinical intervention trial. Long-term use of systemic glucocorticoids, anabolic agents, or other medications that may substantially affect protein or skeletal muscle metabolism. Use of other weight-loss medications, fat-loss supplements, or muscle-enhancing products within the previous 3 months, apart from the prespecified GLP-1RA-related treatment. Use of antibiotics, probiotics, prebiotics, or other products or medications likely to substantially affect the gut microbiota within the previous 1 month.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shenzhen Qianhai Taikang Hospital
Shenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which exercise dose best helps kids with metabolic syndrome?
- Custom knee guides put to the test in obese patients
- A pill for obesity? early human trial puts MDR-001 to the test
- Can a weekly shot help people who still struggle with weight after bariatric surgery?
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?
- Can electrical muscle stimulation boost exercise benefits after menopause?